Alseres Pharmaceuticals (OTCMKTS:ALSE) & Marker Therapeutics (NASDAQ:MRKR) Head-To-Head Survey

Alseres Pharmaceuticals (OTCMKTS:ALSE) and Marker Therapeutics (NASDAQ:MRKR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, institutional ownership and valuation.

Insider and Institutional Ownership

22.4% of Marker Therapeutics shares are owned by institutional investors. 8.9% of Alseres Pharmaceuticals shares are owned by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Alseres Pharmaceuticals and Marker Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alseres Pharmaceuticals	N/A	N/A	N/A
Marker Therapeutics	-343.03%	-73.29%	-59.70%

Valuation and Earnings

This table compares Alseres Pharmaceuticals and Marker Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alseres Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
Marker Therapeutics	$3.55 million	6.17	-$12.16 million	($0.61)	-2.16

Alseres Pharmaceuticals has higher earnings, but lower revenue than Marker Therapeutics.

Analyst Recommendations

This is a summary of recent ratings and target prices for Alseres Pharmaceuticals and Marker Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alseres Pharmaceuticals	0	0	0	0	0.00
Marker Therapeutics	1	1	2	0	2.25

Marker Therapeutics has a consensus price target of $10.00, indicating a potential upside of 660.46%. Given Marker Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Alseres Pharmaceuticals.

Summary

Marker Therapeutics beats Alseres Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Alseres Pharmaceuticals

Alseres Pharmaceuticals, Inc. focuses on developing diagnostic and therapeutic products primarily for disorders in the central nervous system. Its lead product candidate is Altropane, a molecular imaging agent for the diagnosis of Parkinson’s disease and dementia. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

About Marker Therapeutics

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.